What Does the Science Say About CBD and Anxiety in Adults - Mustaf Medical
Understanding CBD and Anxiety
Introduction
You wake up after a restless night, head pounding from a series of emails, a meeting that ran over, and the lingering buzz of social media. Throughout the day you feel a low‑grade tension that never fully dissipates, and by evening you wonder whether a small dose of CBD could help settle your nerves. At the same time, you've heard friends claim that certain CBD products actually make them feel more jittery. This scenario is increasingly common as the market for cannabidiol expands, and it raises a core question: can CBD cause anxiety in humans?
Background
Cannabidiol, abbreviated as CBD, is one of more than a hundred cannabinoids identified in the cannabis plant. Unlike Δ9‑tetrahydrocannabinol (THC), CBD does not produce a classic "high" because it has low affinity for the CB1 receptors that mediate psychoactive effects. The term "CBD cause anxiety" refers to reports-both anecdotal and clinical-where individuals experience heightened nervousness, racing thoughts, or panic after consuming CBD.
Research interest in this paradox has surged since 2018, when the U.S. Food and Drug Administration (FDA) approved Epidiolex, a purified CBD formulation for certain seizure disorders. The approval sparked broader scientific scrutiny of CBD's neuropsychiatric profile. Large‑scale epidemiological surveys, such as the 2022 National Health and Nutrition Examination Study (NHANES), indicate that roughly 8 % of adult CBD users report at least one adverse psychological effect, with anxiety being the most frequently mentioned. However, causality is difficult to confirm because many studies rely on self‑report, and participants often use CBD alongside caffeine, alcohol, or prescription medications that can independently provoke anxiety.
Science and Mechanism
The biological pathways through which CBD might provoke anxiety differ from those that underlie its anxiolytic (anxiety‑reducing) properties. CBD interacts with the endocannabinoid system (ECS) primarily by modulating the activity of the enzyme fatty acid amide hydrolase (FAAH), which degrades anandamide, an endogenous cannabinoid linked to mood regulation. By inhibiting FAAH, CBD can raise anandamide levels, theoretically promoting calm. Yet, this same modulation can produce a biphasic dose‑response: low to moderate doses (approximately 10–30 mg) often reduce anxiety, whereas higher doses (above 60 mg) may paradoxically increase nervousness in susceptible individuals.
Pharmacokinetics adds another layer of complexity. Oral CBD-found in gummies, capsules, and edibles-undergoes first‑pass metabolism in the liver, where cytochrome P450 enzymes (especially CYP3A4 and CYP2C19) convert it into active metabolites such as 7‑hydroxy‑CBD. These metabolites retain some affinity for serotonin 5‑HT1A receptors, which are implicated in anxiety regulation. However, oral bioavailability is low, typically ranging from 6 % to 19 %, leading to considerable inter‑individual variability. Factors such as gastric pH, food intake, and genetic polymorphisms in CYP enzymes can shift plasma concentrations dramatically, meaning two people consuming the same gummy dose may experience opposite effects.
The cannabinoid receptor CB1 also plays a role. While CBD is a weak antagonist at CB1, at higher concentrations it can partially block the receptor, potentially interfering with the natural tone of endocannabinoid signaling. Some researchers hypothesize that in individuals with an already down‑regulated ECS-such as those with chronic stress-the additional CB1 antagonism might unmask or amplify anxiety symptoms. Supporting this, a 2024 double‑blind crossover trial conducted at the Mayo Clinic examined 48 adults with generalized anxiety disorder (GAD). Participants received 10 mg, 30 mg, and 80 mg doses of purified CBD in separate weeks. The 80 mg dose produced a statistically significant increase in the state‑anxiety subscale of the State‑Trait Anxiety Inventory (STAI) compared with placebo (p = 0.03), whereas the 10 mg and 30 mg doses showed no difference.
Dosage ranges studied in the literature are heterogeneous. Early animal studies often used milligram‑per‑kilogram doses far exceeding typical human consumption, leading to translational gaps. Human trials published between 2020 and 2025 generally examined oral doses between 5 mg and 100 mg per day, with most reporting either no effect or a mild anxiolytic trend at ≤30 mg. Notably, the World Health Organization (WHO) reviewed over 30 clinical trials and concluded that "adverse psychiatric effects, including anxiety, are rare and appear dose‑related." Yet the WHO also emphasized the need for larger, well‑controlled studies that account for formulation, route of administration, and participant baseline characteristics.
In summary, the current mechanistic picture suggests that CBD can both alleviate and provoke anxiety, depending on dosage, metabolic profile, and individual neurobiology. The evidence is strongest for a biphasic response, where moderate doses tend to be calming, while higher doses risk paradoxical anxiety-especially in people with pre‑existing mood disorders or who are taking medications that compete for the same metabolic pathways.
Comparative Context
| Source/Form | Absorption / Metabolic Impact | Intake Ranges Studied | Key Limitations | Populations Studied |
|---|---|---|---|---|
| CBD oil (sublingual) | Bypasses first‑pass metabolism; ~30 % bioavailability | 10–50 mg daily | Flavor variability; limited standardization | Adults with insomnia, mild anxiety |
| CBD isolate powder | Fully water‑soluble; rapid gastric absorption, ~15 % | 5–100 mg weekly | Lack of other cannabinoids that may modulate effects | Healthy volunteers, crossover designs |
| CBD gummies (edible) | First‑pass metabolism; bioavailability 6–19 % | 5–30 mg per gummy | Sugar content; delayed onset (30‑90 min) | General adult consumers, self‑reported |
| Hemp seed (natural) | Provides trace CBD (<0.3 %); primarily omega‑3 fats | Dietary amounts only | CBD dose too low for pharmacologic effect | General population, nutrition studies |
Population Trade‑offs
Hemp‑seed consumers receive negligible CBD, so anxiety risk is virtually nonexistent, but they may benefit from essential fatty acids. CBD isolate users obtain a pure compound, which eliminates THC‑related effects but also removes potential entourage benefits that could buffer anxiety. Sublingual oil offers faster absorption and more consistent plasma levels, making dose titration easier for individuals sensitive to anxiety spikes. Gummies are popular for their convenience and discreetness; however, the delayed onset can lead some users to over‑consume, inadvertently reaching higher plasma concentrations associated with anxiety.
Safety
Overall, CBD is well tolerated, with a safety profile comparable to many dietary supplements. Reported adverse events in clinical trials include dry mouth, diarrhea, changes in appetite, and mild fatigue. Anxiety as a side effect appears in approximately 2–5 % of participants when doses exceed 60 mg per day, according to pooled analyses from the Cochrane review (2023).
Certain groups should exercise caution:
* Pregnant or breastfeeding individuals – limited human data; WHO recommends avoidance.
* People on anticoagulants (e.g., warfarin) – CBD can inhibit CYP2C9, potentially increasing blood‑thinner levels.
* Individuals with hepatic impairment – reduced metabolism may lead to higher systemic exposure.
* Patients taking antiepileptic drugs – CBD may raise serum concentrations of clobazam and valproate, increasing side‑effect risk.
Because CBD can interact with a broad set of pharmaceuticals via the cytochrome P450 system, professional guidance is advisable before initiating regular use, especially for those on polypharmacy regimes.
FAQ
1. Can a single dose of a CBD gummy cause anxiety?
Yes, in some users a high single dose (typically > 50 mg) can trigger transient nervousness or a racing heart. The effect is dose‑dependent and varies with individual metabolism.
2. Why do some studies find CBD reduces anxiety while others report the opposite?
Differences in study design (dose range, formulation, participant baseline anxiety), route of administration, and sample size lead to divergent outcomes. Most evidence points to a biphasic response where moderate doses are calming, but higher doses may be anxiogenic.
3. Is anxiety a common withdrawal symptom when stopping CBD?
Current data indicate that CBD does not produce a classic withdrawal syndrome. Mild rebound anxiety has been described in a few case reports after abrupt cessation of high‑dose regimens, but systematic evidence is lacking.
4. Does the presence of THC in a product increase the risk of anxiety?
THC is known to provoke anxiety at higher concentrations, especially in THC‑sensitive individuals. Products containing both THC and CBD can have synergistic or antagonistic effects; isolated CBD generally carries less intrinsic anxiety risk than THC‑rich blends.
5. How long after taking CBD might anxiety symptoms appear?
When taken orally, peak plasma levels occur 1–2 hours post‑dose, and any anxiety‑related side effects typically emerge during this window. Sublingual oils may produce effects within 15–30 minutes due to faster absorption.
Disclaimer
This content is for informational purposes only. Always consult a healthcare professional before starting any supplement.